Skip to content
Back to Compounds

Caffeine

Stimulant (xanthine alkaloid).

At a glance5 outcomes graded

Safety notes
Evidence last reviewed Added to the site 38 studies citedEditorial review: NootropicsWork Editorial TeamEducational, not medical advice

Bottom line

Caffeine is a stimulant found in coffee, tea and cocoa [39]. In placebo-controlled trials it improved attention and reaction time in rested healthy adults [2] and endurance in exercisers [5]. Taken within hours of bedtime, it shortened sleep and delayed sleep onset [8]. Side effects rose with dose in athletes [12], and pure caffeine powders have been linked to deaths [42].

Key takeaways

  • In a 2025 meta-analysis of 31 placebo-controlled trials (1,455 rested healthy adults), caffeine improved accuracy and reaction time on attention tests [2].
  • An umbrella review of 21 meta-analyses found moderate-quality evidence that caffeine improves aerobic endurance; most participants were young men [5].
  • In a meta-analysis of 24 studies of night-time sleep, caffeine reduced total sleep time by 45 minutes and added 9 minutes to the time taken to fall asleep [8].
  • Daily use brings partial tolerance, and withdrawal symptoms appeared after stopping intakes as low as 100 mg a day [13][24][25].
  • Some medicines slow caffeine clearance sharply: in one small study, a medicine raised caffeine's half-life from 5 to 31 hours [16].

Evidence by outcome

Attention

A, strong. Benefit foundEvidence maturity: Established

Yes, in the short term.

4 studies linkedShort-term only
Why A, and history for Attention

A 2025 meta-analysis of 31 randomized, double-blind, placebo-controlled trials (1,455 rested healthy adults) found better accuracy on attention tests (g = 0.27); it was publicly funded and the effect did not vary with habitual intake. In other populations, a meta-analysis in sleep-deprived people and a Cochrane review in shift workers point the same way, though the Cochrane trials had a high risk of bias; neither is part of this grade. A focused review argues that in habitual users much of the acute benefit may reflect reversal of withdrawal, so the grade covers acute effects only.

Rubric condition met: A meta-analysis of 31 placebo-controlled RCTs in rested healthy adults with a consistent direction, publicly funded.

Grade history

  • : Graded A (awaiting approval)
  • : A to A (awaiting approval). Maturity, bias summary and re-check date added
  • : A to A (approved). Editor sign-off November 16, 2026: grade matches the editor-approved final page

Studies and full rationale for Attention

How sure are we? Attention

Evidence maturity: Established A 2025 meta-analysis of 31 randomized, double-blind, placebo-controlled trials in rested healthy adults, publicly funded, plus a preregistered independent RCT (NCT02461693, 205 enrolled, registered June 1, 2015 at the start of enrollment).

Who paid for the studies
Mostly independent
Risk of bias
Not assessed: the 2025 meta-analysis abstract reports no risk-of-bias rating and the full text was not read
Trial registry check
NCT02461693 registered at the start of enrollment (first submitted June 1, 2015; start June 2015); primary outcomes include vigilance proportion correct and mean time to a correct hit
Publication bias
Not assessed: no funnel or small-study test reported in the abstracts read
Outcome measured
A test score, rating scale or performance measure
Who was studied
Matched
Doses used in studies
About 40-300 mg (0.5-4 mg/kg) single doses; effects below and above 200 mg
  • Could rise: Already at the top grade.
  • Could fall: Would move to B if an independent, preregistered RCT of 100 or more rested habitual users, with a washout control, found no effect on its primary attention outcome.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Reaction time

A, strong. Benefit foundEvidence maturity: Established

In trials, yes.

3 studies linkedShort-term only
Why A, and history for Reaction time

In the 2025 meta-analysis of 31 placebo-controlled trials in rested healthy adults, caffeine shortened reaction time (g = 0.28), and reaction time kept improving as the dose rose. A review of military and occupational studies found faster reaction time after low to moderate doses. The grade covers acute effects only.

Rubric condition met: A meta-analysis of 31 placebo-controlled RCTs in rested healthy adults with a consistent direction, publicly funded.

Grade history

  • : Graded A (awaiting approval)
  • : A to A (awaiting approval). Maturity, bias summary and re-check date added
  • : A to A (approved). Editor sign-off November 16, 2026: grade matches the editor-approved final page

Studies and full rationale for Reaction time

How sure are we? Reaction time

Evidence maturity: Established The same 31-trial meta-analysis and preregistered independent RCT (NCT02461693, primary outcome includes mean time to a correct hit) as the attention grade.

Who paid for the studies
Mostly independent
Risk of bias
Not assessed: the 2025 meta-analysis abstract reports no risk-of-bias rating and the full text was not read
Trial registry check
NCT02461693 registered at the start of enrollment (first submitted June 1, 2015; start June 2015)
Publication bias
Not assessed: no funnel or small-study test reported in the abstracts read
Outcome measured
A test score, rating scale or performance measure
Who was studied
Matched
Doses used in studies
About 40-300 mg single doses; reaction time kept improving with dose
  • Could rise: Already at the top grade.
  • Could fall: Would move to B if an independent, preregistered RCT of 100 or more rested habitual users, with a washout control, found no effect on reaction time as its primary outcome.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Endurance performance

A, strong. Benefit foundEvidence maturity: Maturity under review

Yes, for many kinds of exercise.

10 studies linked
Why A, and history for Endurance performance

An umbrella review of 21 meta-analyses found moderate-quality evidence that caffeine improves aerobic endurance, and a corrected meta-analysis of 44 placebo-controlled studies found a small benefit on time-trial completion time (effect size 0.28). Newer meta-analyses of 23 to 48 studies agree on direction; most found doses of 3 mg/kg or less also helped. Most participants were young men; a 2026 meta-analysis of 19 trials in 235 women found a small benefit. Most trials are small crossovers, but a 101-athlete randomized trial found a 3% faster 10-km time overall and a slower time in one CYP1A2 genotype group, so the evidence is mixed by individual.

Rubric condition met: Multiple meta-analyses of placebo-controlled trials with a consistent direction, summarized by an umbrella review rating aerobic endurance evidence as moderate quality.

Grade history

  • : Graded A (awaiting approval)
  • : A to A (approved). Editor sign-off November 16, 2026: grade matches the editor-approved final page

Studies and full rationale for Endurance performance

How sure are we? Endurance performance

Evidence maturity: Maturity under review

The maturity label for this grade is under review.

Who paid for the studies
Mixed
Risk of bias
Some concerns: the 2026 meta-analysis in women rated overall risk of bias as some concerns; the other abstracts read report no rating
Trial registry check
Full search on November 15, 2026 (all 261 completed ClinicalTrials.gov records for exercise terms, all 302 ISRCTN caffeine records, PubMed registry-linked records): preregistered endurance trials with published results exist (NCT02109783, n 101), but each found had an industry collaborator, funder or product donor; no independent one found. ANZCTR and OSF not searched directly
Publication bias
Not assessed: no funnel or small-study test reported in the abstracts read
Outcome measured
A test score, rating scale or performance measure
Who was studied
Matched
Doses used in studies
3-6 mg/kg body mass; most newer pooled analyses found 3 mg/kg or less also cut time-trial completion time, one 2024 analysis did not
Rules applied
B5: small studies (logged, no further change): Not applicable: a supporting randomized, double-blind trial enrolled 101 competitive male athletes (Guest 2018, NCT02109783).
  • Could rise: Already at the top grade; the maturity label is under review.
  • Could fall: The maturity label is under review. Would move to B if a meta-analysis restricted to low-risk-of-bias trials showed no effect on endurance.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Sleep latency

A, strong. Evidence of harmEvidence maturity: Maturity under review

Yes.

3 studies linked
Why A, and history for Sleep latency

In healthy adults given caffeine within hours of night-time sleep, a 2023 meta-analysis of 24 studies found caffeine added 9 minutes to the time taken to fall asleep, and a 2025 meta-analysis of 22 crossover trials of acute doses (956 participants) found 8.35 minutes. Both high and low doses lengthened sleep onset. A home trial found 400 mg disturbed sleep even 6 hours before bed. This grade describes a harmful effect.

Rubric condition met: Two meta-analyses of controlled trials in healthy adults with a consistent direction (adverse).

Grade history

  • : Graded A (awaiting approval)
  • : A to A (approved). Editor sign-off November 16, 2026: grade matches the editor-approved final page

Studies and full rationale for Sleep latency

How sure are we? Sleep latency

Evidence maturity: Maturity under review

The maturity label for this grade is under review.

Who paid for the studies
Mostly independent
Risk of bias
Not assessed: the 2023 and 2025 meta-analysis abstracts report no risk-of-bias rating and the full texts were not read
Trial registry check
Full search on November 15, 2026 (all 122 completed ClinicalTrials.gov records for sleep terms, all 302 ISRCTN caffeine records, PubMed registry-linked records): no preregistered independent trial of caffeine alone on sleep in healthy adults with published results found
Publication bias
Not assessed: no funnel or small-study test reported in the abstracts read
Outcome measured
A test score, rating scale or performance measure
Who was studied
Matched
Doses used in studies
Acute doses up to 400 mg, 0-6 hours before bed
  • Could rise: Already at the top grade (adverse); the maturity label is under review.
  • Could fall: Would move to B adverse if two adequately sized preregistered trials found no change in sleep onset at doses of 100 mg or more taken in the morning.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Total sleep time

B, moderate. Evidence of harmEvidence maturity: Emerging

Probably, when taken within hours of bedtime.

5 studies linked
Why B, and history for Total sleep time

In healthy adults given caffeine within hours of night-time sleep, a 2023 meta-analysis of 24 studies found 45 minutes less total sleep and 11.4 minutes less deep sleep, and a 2025 meta-analysis of 22 crossover trials (956 participants) found 34.67 minutes less, in both young and middle-aged groups. A 2025 meta-analysis of 10 studies in 128 athletes taking caffeine before evening training found a non-significant trend in the same direction, and a 10-day trial of daytime use found no change. This grade describes a harmful effect.

Rubric condition met: Two meta-analyses of controlled trials in healthy adults with a consistent direction (adverse).

Grade history

  • : Graded B (awaiting approval)
  • : B to B (approved). Editor sign-off November 16, 2026: grade matches the editor-approved final page

Studies and full rationale for Total sleep time

How sure are we? Total sleep time

Evidence maturity: Emerging Two meta-analyses of controlled trials in healthy adults (24 studies; 22 crossover trials with 956 participants). No preregistered independent trial of caffeine alone on sleep in healthy adults with published results was found in a full registry search on November 15, 2026, so the Established label is not met.

Who paid for the studies
Mostly independent
Risk of bias
Not assessed: the 2023 and 2025 meta-analysis abstracts report no risk-of-bias rating; the 2025 athlete meta-analysis used RoB 2 and ROBINS-I but its abstract gives no ratings
Trial registry check
Full search on November 15, 2026 (all 122 completed ClinicalTrials.gov records for sleep terms, all 302 ISRCTN caffeine records, PubMed registry-linked records): none found
Publication bias
Not assessed: no funnel or small-study test reported in the abstracts read
Outcome measured
A test score, rating scale or performance measure
Who was studied
Matched
Doses used in studies
Acute doses up to 400 mg, 0-6 hours before bed; daytime use at 3 x 150 mg a day did not change total sleep time in one trial
  • Could rise: Would move to A adverse if a preregistered, independent RCT in healthy adults found shorter total sleep after caffeine on its primary outcome.
  • Could fall: Would move to C adverse if a meta-analysis restricted to low-risk-of-bias trials found no change in total sleep time after doses taken within hours of bedtime.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Maturity sits beside each grade. The grade says what the evidence shows; maturity says how much of it there is and how well it is confirmed.

Established
many trials from several independent teams, including at least one registered in advance
Emerging
two or more trials, or one large registered trial, not yet independently confirmed
Early signal
one trial, small pilots, or results only on secondary outcomes
Mechanistic only
lab, animal or biomarker data, or uncontrolled reports; no controlled human results
Traditional use only
a traditional-use monograph and nothing else

Grades describe evidence for each outcome, not a recommendation. Open “Why” on a card for its rationale and dated grade history. How we grade

The grades below cover acute use, meaning effects in the hours after a dose. Our evidence grading method explains what each grade and maturity label requires.

Does caffeine improve attention?

Yes, in the short term. A 2025 meta-analysis pooled 31 randomized, double-blind, placebo-controlled trials with 1,455 rested healthy adults and found caffeine improved accuracy on attention tests (g = 0.27, a small effect) [2]. The effect was not related to how much caffeine people usually consumed, how complex the task was or which attention network was tested [2]. That review was publicly funded by Danmarks Frie Forskningsfond, and its authors declared no conflicts [2].

Dose matters, but not in a straight line. Doses of 200 mg or more improved accuracy more than lower doses, yet accuracy improved only up to a point before declining [2]. A military and occupational review found alertness, vigilance and attention improve after low (about 40 mg) to moderate (about 300 mg) doses, while effects on memory and judgment are less consistent [1].

Other populations show the same direction. A meta-analysis of 45 publications in sleep-deprived people found better accuracy on attention tests (g = 0.68) [3], and a Cochrane review of 13 mostly simulated trials in shift workers found better orientation and attention (SMD -0.55), with a high risk of bias [19].

One preregistered trial (NCT02461693, 205 adults, a single 200 mg dose against placebo) was designed to separate the drug's effect from expectation [52]; its authors reported that some effects differed by whether people expected the active drug [20].

Does caffeine improve reaction time?

In trials, yes. In the same 31-trial meta-analysis, caffeine shortened reaction time on attention tests (g = 0.28), and unlike accuracy, reaction time kept improving as the dose rose [2]. The military and occupational review also found faster reaction time after low to moderate doses [1].

Does caffeine improve endurance?

Yes, for many kinds of exercise. An umbrella review of 21 meta-analyses found moderate-quality evidence that caffeine improves aerobic endurance, muscle endurance, strength and anaerobic power, with larger effects for aerobic exercise [5]. The corrected version of a 2018 meta-analysis of 44 placebo-controlled studies reports an overall effect size of 0.28 for time-trial completion time and a small effect at moderate doses of 3-6 mg/kg [6].

Newer pooled studies agree on direction but not fully on the lowest helpful dose. A 2024 meta-analysis of 15 crossover studies found 4-6 mg/kg cut completion time (SMD -0.55) while 1-3 mg/kg did not reach significance [21]. Later analyses of 20 studies [23], of 48 studies with 689 participants [32] and of 48 studies in a network meta-analysis (SMD -0.34 for low-dose capsules) [33] found that 3 mg/kg or less did cut completion time, though one found moderate doses more consistent [32]. A 2026 meta-analysis of 23 double-blind trials in cyclists found a small benefit (SMD -0.32, I² = 0%) [34].

Most participants were young men [5]; a 2026 meta-analysis of 19 crossover trials in 235 women found a small benefit (SMD 0.21), with risk of bias rated "some concerns" [22]. Most trials are small crossovers, but one double-blind trial randomized 101 competitive male athletes and was registered before it began, with an industry collaborator [31][54]. Overall, 4 mg/kg cut 10-km cycling time by 3%, but in men with the CC genotype of the CYP1A2 gene it increased cycling time by 13.7%, and the AC group showed no effect [31]. The 2018 review also found two studies with slower times [6]. The evidence is mixed by individual.

Does caffeine delay sleep onset?

Yes. This grade describes the strength of evidence for a harmful effect. In studies of night-time sleep after doses taken within hours of bed, a 2023 meta-analysis of 24 studies found caffeine added 9 minutes to the time taken to fall asleep and 12 minutes awake after falling asleep [8]. A 2025 meta-analysis of 22 crossover trials of acute doses (956 healthy adults) found 8.35 minutes [10]. High and low doses both lengthened sleep onset, and differences by age and dose were not statistically significant [10].

Timing matters. In a placebo-controlled home study, 400 mg taken at bedtime, 3 hours or 6 hours before bed all disturbed sleep [9]. The 2023 meta-analysis estimated that total sleep was not reduced when a 107 mg coffee was finished at least 8.8 hours before bed, or a 217.5 mg pre-workout serving at least 13.2 hours before [8].

Does caffeine shorten total sleep?

Probably, when taken within hours of bedtime. This is also an adverse grade. Caffeine cut total sleep time by 45 minutes, sleep efficiency by 7% and deep sleep by 11.4 minutes in the 2023 meta-analysis [8], and total sleep by 34.67 minutes, in young and middle-aged groups, in the 2025 one [10].

Not every study agrees. A 2025 meta-analysis of 10 studies in 128 athletes taking caffeine before late-afternoon or evening training found a non-significant trend toward less total sleep (-32.47 minutes, p = 0.08) [35]. In a trial of 20 male habitual users taking 150 mg three times a day for 10 days, total sleep did not differ from placebo; recording began 5 hours after usual bedtime [36].

Does tolerance cancel the benefit?

Partly. In a crossover trial of 11 active adults taking 3 mg/kg daily for 20 days, caffeine raised peak cycling power by about 4% for the first 15 days, then the effect lessened [24]. In a crossover trial of 12 volunteers given 200 mg twice daily for a week, tolerance was incomplete, and cognitive performance was not affected by previous caffeine exposure [25].

For mental performance, a focused review argues that placebo-controlled studies cannot separate a true benefit from reversal of withdrawal in regular users, and that long-term withdrawal studies find little net benefit over abstinence [4]. Against that, the 2025 meta-analysis found the attention benefit did not vary with habitual intake [2]. Our grades cover acute effects only.

What happens when regular users stop?

A review of 57 experimental and 9 survey studies confirmed withdrawal symptoms including headache, fatigue, low energy, drowsiness, low mood, difficulty concentrating and irritability [13]. Symptoms typically began 12-24 hours after the last dose, peaked at 20-51 hours and lasted 2-9 days, and headache occurred in 50% of people in experimental studies [13]. Stopping intakes as low as 100 mg a day produced symptoms [13].

Caffeine plus L-theanine

Tea combines caffeine with the amino acid L-theanine. A 2014 meta-analysis of 11 placebo-controlled studies found moderate effects favoring the pair on alertness and attention-switching accuracy in the first 2 hours [26]. A 2025 meta-analysis co-funded by Lipton Teas and Infusions, with authors employed by Lipton and Unilever, found better attention-switching accuracy in the second hour (SMD 0.33), with wide uncertainty around most estimates [27]. The pair is graded on our L-theanine page and covered in our guide to caffeine and L-theanine.

What the evidence does not show

Effects on memory and complex judgment are less consistent than effects on alertness and reaction time [1]. Whether daily, long-term use gives a net mental benefit over not using caffeine at all remains disputed [4].

How sure are we?

On November 15, 2026 we searched all completed caffeine records in ClinicalTrials.gov (261 exercise and 122 sleep records), all 302 in ISRCTN, and PubMed for registered trials. Each preregistered endurance trial we found with published results had an industry funder, collaborator or product donor [31][54], and we found none for sleep in healthy adults, so total sleep time is Emerging [10]. Science is provisional. These grades reflect the evidence we found as of November 15, 2026.

What people report and traditional use: not evidence of effect

These sources describe experience or history. They can't show that caffeine caused an effect. Checked .

Doses used in studies

Ranges researchers used, not dosing advice. Bars share one scale. Read our disclaimer.

Alertness, attention and reaction timeAbout 40 mg (0.5 mg/kg) to about 300 mg (4 mg/kg); 200 mg or more improved attention outcomes more than lower doses0.5 to 300 mg
Endurance exercise3-6 mg/kg body mass

3-6 mg/kg body mass

Time trialsLow (3 mg/kg or less) and moderate (4-6 mg/kg) doses compared

Low (3 mg/kg or less) and moderate (4-6 mg/kg) doses compared

Daily-use tolerance trial3 mg/kg a day for 20 days

3 mg/kg a day for 20 days

Sleep disruption trial400 mg at 0, 3 or 6 hours before bed400 mg

Timing and form

Taken by mouth, caffeine is absorbed rapidly and completely, and its stimulating effects may begin 15 to 30 minutes after ingestion and last a number of hours [39]. EFSA reports an average half-life (the time the body takes to clear half a dose) of about four hours in healthy adults, with a range of two to eight hours [39]. Clearance varies with age, sex and hormones, liver disease, obesity, smoking and diet [14].

In exercise research, the most commonly used timing is 60 minutes before exercise, and caffeinated chewing gums, mouth rinses, energy gels and chews have also been studied [7].

What it is

Caffeine is a naturally occurring compound found in coffee and cocoa beans, tea leaves, guarana berries and the kola nut [39]. It is a xanthine alkaloid and the most commonly used psychoactive drug in the world [48]. LiverTox puts typical amounts at 80 to 175 mg per cup of coffee and 20 to 80 mg per cup of tea, and says over-the-counter tablets generally contain 100 or 200 mg [48].

How it works (mechanism, not effect): caffeine blocks adenosine receptors [1]. The liver enzyme CYP1A2 metabolizes about 95% of the caffeine people take in [14].

Safety and interactions

Safety flag. In a 2026 meta-analysis of randomized trials in athletes (940 participants), caffeine raised the odds of headache, abdominal discomfort, rapid heartbeat, trouble sleeping, anxiety and nervousness compared with placebo, with several rising with dose [12]. A meta-analysis of 8 randomized trials in adults found caffeine supplementation raised systolic blood pressure by 1.94 mmHg and diastolic by 1.66 mmHg [28]. FDA estimates toxic effects such as seizures with rapid consumption of about 1,200 mg, without stating the evidence behind the estimate, and says pure and highly concentrated caffeine products have contributed to at least two deaths in the United States [41][42]. An analysis of 216 published case reports states that doses of 5-10 g can be lethal; case reports can't show how common harm is [29]. LiverTox rates caffeine as an unlikely cause of clinically apparent liver injury (likelihood score E) [48]. Withdrawal symptoms such as headache, fatigue and difficulty concentrating typically began 12-24 hours after the last dose and lasted 2-9 days [13]. LactMed reports that caffeine appears in breast milk rapidly and that preterm and newborn infants clear it very slowly [49]; in a study of 7 infants, caffeine clearance reached adult rates at 3 to 4 1/2 months of age [38].

Who sources say should be careful.

  • Pregnant women. EFSA concluded intakes up to 200 mg a day raise no safety concerns for the fetus, basing this on cohort studies of birth weight outcomes [40]. The NHS advises no more than 200 mg a day, citing a link to miscarriage and stillbirth [47]; a dose-response meta-analysis of 53 cohort and case-control studies found modest associations within usual intakes that may reflect bias in study design or publication [18]. Health Canada recommends no more than 300 mg a day [43].

  • Breastfeeding. LactMed reports that caffeine appears in breast milk rapidly, that fussiness, jitteriness and poor sleep were reported in infants of mothers drinking about 10 or more cups of coffee a day, and that preterm and newborn infants clear it very slowly [49]; in 7 infants, clearance reached adult rates at 3 to 4 1/2 months of age [38].

  • Children and adolescents. Health Canada recommends no more than 2.5 mg/kg a day, and calls this a precautionary approach based on limited data [43].

  • People with advanced liver disease, who may clear caffeine slowly [48][14].

  • People taking CYP1A2-blocking medicines, as described above [15][16].

Side effects rise with dose. In a 2026 meta-analysis of randomized trials in athletes (940 participants), caffeine raised the odds of headache, abdominal discomfort, rapid heartbeat, trouble sleeping, anxiety and nervousness compared with placebo, and higher doses were linked to more of several of these [12]. A meta-analysis of 8 randomized trials in adults found caffeine supplementation raised systolic blood pressure by 1.94 mmHg and diastolic by 1.66 mmHg [28]. LiverTox rates caffeine as an unlikely cause of liver injury, and reports no evidence that regular caffeine or coffee intake harms the liver [48].

High doses can be dangerous. FDA estimates that toxic effects such as seizures can occur with rapid consumption of about 1,200 mg; its page does not state the evidence behind this estimate [41]. FDA says pure and highly concentrated caffeine products have contributed to at least two deaths in the United States [42]. An analysis of 216 published case reports states that doses of 5-10 g can be lethal and that 21% of accidental intoxications were in minors; such reports can't show how common harm is [29].

Regulators cite intake levels of no safety concern; these are precautionary thresholds, not doses at which harm was seen. EFSA's 2015 opinion concluded that single doses up to 200 mg and habitual intakes up to 400 mg a day raise no safety concerns for healthy non-pregnant adults [40]. It based the single-dose figure mainly on supplement trials measuring heart blood flow, hydration, body temperature, perceived effort and sleep, and the daily figure on earlier assessments by other bodies that raised no concerns [40]. For children and adolescents it found the information insufficient and extended the adult single-dose figure of 3 mg/kg, citing limited studies of anxiety and behavior [40]. FDA cites 400 mg a day for most adults as not generally associated with negative effects, citing a 2017 systematic review [41] funded by the ILSI North America Caffeine Working Group, whose funders included the American Beverage Association and the National Coffee Association [11]. That review found intakes up to 400 mg a day in healthy adults were not associated with overt adverse cardiovascular, behavioral, reproductive or bone effects [11]. Health Canada bases its recommended maximums on its own scientists' review of several studies [43].

Interactions sources report

Because CYP1A2 clears most caffeine, medicines that block this enzyme can raise caffeine levels [14]. A pharmacology review lists strong CYP1A2 inhibitors including fluvoxamine, mexiletine, clozapine, furafylline, theophylline and the quinolone antibiotic enoxacin [15]. In eight healthy volunteers, fluvoxamine increased caffeine's half-life from 5 to 31 hours [16]. In 12 healthy men, the quinolones enoxacin and pipemidic acid markedly slowed caffeine elimination, and ciprofloxacin at doses in the upper part of the recommended range slowed it about 1.5-fold [17]. NIH ODS notes that cimetidine can slow caffeine clearance and raise the risk of side effects [50]; in a small randomized crossover study in five healthy people, cimetidine reduced caffeine clearance and prolonged its half-life [37]. The EMA guarana monograph says caffeine-containing preparations reduce sedative action and increase side effects of sympathomimetic drugs, and advises caution with MAO-inhibitor drugs [51].

If you take any of these medicines, talk to your doctor or pharmacist before combining them with caffeine.

Products containing it

Partner product: we earn a commission

Qualia Mind 2.0

Contains this compound among other ingredients. Our review compares each dose with the doses used in studies.

Read our review

FAQ

How long does caffeine stay in your system?

EFSA reports an average half-life of about four hours in healthy adults, with a range of two to eight hours [39]. Age, hormones, liver health, smoking and diet change how fast it is cleared [14].

Does caffeine stop working if you use it every day?

Partly. In a 20-day trial, the performance benefit lessened after about 15 days [24], while a meta-analysis found the attention benefit was not related to habitual intake [2]. Withdrawal symptoms appeared after stopping intakes as low as 100 mg a day [13].

How much caffeine is too much?

EFSA and FDA cite up to 400 mg a day for healthy adults, and EFSA 200 mg a day in pregnancy [40][41]. These are precautionary levels of no concern, resting on human studies reviewed by EFSA and on a 2017 industry-funded review cited by FDA [40][11]. FDA estimates toxic effects with rapid intake of about 1,200 mg but does not state the basis [41]. Talk to a clinician about your own situation.

References

  1. McLellan TM, Caldwell JA, Lieberman HR. A review of caffeine's effects on cognitive, physical and occupational performance. Neurosci Biobehav Rev. 2016.PMID 27612937DOI 10.1016/j.neubiorev.2016.09.001Tier 1, narrative review
  2. Kløve K, Petersen A. A systematic review and meta-analysis of the acute effect of caffeine on attention. Psychopharmacology (Berl). 2025.PMID 40335666DOI 10.1007/s00213-025-06775-1Tier 1, meta-analysis
  3. Irwin C, Khalesi S, Desbrow B, et al. Effects of acute caffeine consumption following sleep loss on cognitive, physical, occupational and driving performance: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2020.PMID 31837359DOI 10.1016/j.neubiorev.2019.12.008Tier 1, meta-analysis
  4. James JE, Rogers PJ. Effects of caffeine on performance and mood: withdrawal reversal is the most plausible explanation. Psychopharmacology (Berl). 2005.PMID 16001109DOI 10.1007/s00213-005-0084-6Tier 1, meta-analysis
  5. Grgic J, Grgic I, Pickering C, et al. Wake up and smell the coffee: caffeine supplementation and exercise performance-an umbrella review of 21 published meta-analyses. Br J Sports Med. 2020.PMID 30926628DOI 10.1136/bjsports-2018-100278Tier 1, meta-analysis
  6. Southward K, Rutherfurd-Markwick KJ, Ali A. The Effect of Acute Caffeine Ingestion on Endurance Performance: A Systematic Review and Meta-Analysis. Sports Med. 2018.PMID 29876876DOI 10.1007/s40279-018-0939-8Tier 1, meta-analysis
  7. Guest NS, VanDusseldorp TA, Nelson MT, et al. International society of sports nutrition position stand: caffeine and exercise performance. J Int Soc Sports Nutr. 2021.PMID 33388079DOI 10.1186/s12970-020-00383-4Tier 1, narrative review
  8. Gardiner C, Weakley J, Burke LM, et al. The effect of caffeine on subsequent sleep: A systematic review and meta-analysis. Sleep Med Rev. 2023.PMID 36870101DOI 10.1016/j.smrv.2023.101764Tier 1, meta-analysis
  9. Drake C, Roehrs T, Shambroom J, et al. Caffeine effects on sleep taken 0, 3, or 6 hours before going to bed. J Clin Sleep Med. 2013.PMID 24235903DOI 10.5664/jcsm.3170Tier 1, RCT
  10. Chang YH, Cheng YC, Cheng WJ. Age- and dose-specific effects of caffeine on sleep: A meta-analysis of controlled crossover trials. Sleep Med. 2025.PMID 41124973DOI 10.1016/j.sleep.2025.106874Tier 1, meta-analysis
  11. Wikoff D, Welsh BT, Henderson R, et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol. 2017.PMID 28438661DOI 10.1016/j.fct.2017.04.002Tier 1, systematic review
  12. Negaresh R, Al-Riyami SAA, Ghahfarrokhi MM, et al. Caffeine Use in Sport: A Systematic Review and Meta-analysis of Acute Side Effects and Implications for Athlete Health and Safety. Sports Med. 2026.PMID 42033594DOI 10.1007/s40279-026-02441-4Tier 1, meta-analysis
  13. Juliano LM, Griffiths RR. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology (Berl). 2004.PMID 15448977DOI 10.1007/s00213-004-2000-xTier 1, narrative review
  14. Nehlig A. Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption. Pharmacol Rev. 2018.PMID 29514871DOI 10.1124/pr.117.014407Tier 1, narrative review
  15. Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000.PMID 10976659DOI 10.2165/00003088-200039020-00004Tier 1, narrative review
  16. Jeppesen U, Loft S, Poulsen HE, et al. A fluvoxamine-caffeine interaction study. Pharmacogenetics. 1996.PMID 8807660DOI 10.1097/00008571-199606000-00003Tier 1, RCT
  17. Harder S, Fuhr U, Staib AH, et al. Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations. Am J Med. 1989.PMID 2589393DOI 10.1016/0002-9343(89)90031-4Tier 1
  18. Greenwood DC, Thatcher NJ, Ye J, et al. Caffeine intake during pregnancy and adverse birth outcomes: a systematic review and dose-response meta-analysis. Eur J Epidemiol. 2014.PMID 25179792DOI 10.1007/s10654-014-9944-xTier 1, meta-analysis
  19. Ker K, Edwards PJ, Felix LM, et al. Caffeine for the prevention of injuries and errors in shift workers. Cochrane Database Syst Rev. 2010.PMID 20464765DOI 10.1002/14651858.CD008508Tier 1, meta-analysis
  20. George BJ, Li P, Lieberman HR, et al. Randomization to randomization probability: Estimating treatment effects under actual conditions of use. Psychol Methods. 2018.PMID 28406674DOI 10.1037/met0000138Tier 1
  21. Chen B, Ding L, Qin Q, et al. Effect of caffeine ingestion on time trial performance in cyclists: a systematic review and meta-analysis. J Int Soc Sports Nutr. 2024.PMID 38836626DOI 10.1080/15502783.2024.2363789Tier 1, meta-analysis
  22. Bittencourt de Santa Ritta G, Brito Soares LM, Abreu ACP, et al. Addressing the Evidence Gap: Ergogenic Effects of Caffeine on Cycling Performance in Females-A Systematic Review and Three-Level Meta-Analysis. Int J Sport Nutr Exerc Metab. 2026.PMID 42208612DOI 10.1123/ijsnem.2026-0022Tier 1, meta-analysis
  23. Wu J, Xu K, Yin M, et al. Effect of caffeine ingestion on cycling performance: a systematic review and meta-analysis. Front Nutr. 2025.PMID 41601907DOI 10.3389/fnut.2025.1745472Tier 1, systematic review
  24. Lara B, Ruiz-Moreno C, Salinero JJ, et al. Time course of tolerance to the performance benefits of caffeine. PLoS One. 2019.PMID 30673725DOI 10.1371/journal.pone.0210275Tier 1, RCT
  25. Watson J, Deary I, Kerr D. Central and peripheral effects of sustained caffeine use: tolerance is incomplete. Br J Clin Pharmacol. 2002.PMID 12392588DOI 10.1046/j.1365-2125.2002.01681.xTier 1, RCT
  26. Camfield DA, Stough C, Farrimond J, et al. Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis. Nutr Rev. 2014.PMID 24946991DOI 10.1111/nure.12120Tier 1, meta-analysis
  27. Payne ER, Aceves-Martins M, Dubost J, et al. Effects of Tea (Camellia sinensis) or its Bioactive Compounds l-Theanine or l-Theanine plus Caffeine on Cognition, Sleep, and Mood in Healthy Participants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutr Rev. 2025.PMID 40314930DOI 10.1093/nutrit/nuaf054Tier 1, meta-analysis
  28. Abbas-Hashemi SA, Hosseininasab D, Rastgoo S, et al. The effects of caffeine supplementation on blood pressure in adults: A systematic review and dose-response meta-analysis. Clin Nutr ESPEN. 2023.PMID 38057002DOI 10.1016/j.clnesp.2023.09.923Tier 1, meta-analysis
  29. Uehlein S, Dechant K, Stahl K, et al. Caffeine Intoxication: An Analysis of Published Case Reports, 1883–2023. Dtsch Arztebl Int. 2025.PMID 40632678DOI 10.3238/arztebl.m2025.0113Tier 1, narrative review
  30. Ágoston C, Urbán R, Király O, et al. Why Do You Drink Caffeine? The Development of the Motives for Caffeine Consumption Questionnaire (MCCQ) and Its Relationship with Gender, Age and the Types of Caffeinated Beverages. Int J Ment Health Addict. 2018.PMID 30147634DOI 10.1007/s11469-017-9822-3Tier 1
  31. Guest N, Corey P, Vescovi J, et al. Caffeine, CYP1A2 Genotype, and Endurance Performance in Athletes. Med Sci Sports Exerc. 2018.PMID 29509641DOI 10.1249/MSS.0000000000001596Tier 1, RCT
  32. Martins GL, Aparecido JM, Marquezi ML, et al. Dose-Response Effect of Oral Caffeine Use on Aerobic Exercise Performance: A Systematic Review and Meta-Analysis. Nutrients. 2026.PMID 42356375DOI 10.3390/nu18121989Tier 1, meta-analysis
  33. Xue R, Huang J, Chen B, et al. Effects of Caffeine Dose and Administration Method on Time-Trial Performance: A Systematic Review and Network Meta-Analysis. Nutrients. 2025.PMID 41374083DOI 10.3390/nu17233792Tier 1, systematic review
  34. Wang Z, Zhang J, Cho C. Acute caffeine supplementation and cycling time-trial performance across different task durations: a systematic review and meta-analysis. Front Physiol. 2026.PMID 42445506DOI 10.3389/fphys.2026.1853564Tier 1, systematic review
  35. Kocak A, Georgousopoulou E, Knight-Agarwal CR, et al. The Effect of Consuming Caffeine Before Late Afternoon/Evening Training or Competition on Sleep: A Systematic Review with Meta-Analysis. Sports (Basel). 2025.PMID 41003623DOI 10.3390/sports13090317Tier 1, narrative review
  36. Weibel J, Lin YS, Landolt HP, et al. Regular Caffeine Intake Delays REM Sleep Promotion and Attenuates Sleep Quality in Healthy Men. J Biol Rhythms. 2021.PMID 34024173DOI 10.1177/07487304211013995Tier 1, RCT
  37. Broughton LJ, Rogers HJ. Decreased systemic clearance of caffeine due to cimetidine. Br J Clin Pharmacol. 1981.PMID 7306430DOI 10.1111/j.1365-2125.1981.tb01194.xTier 1, RCT
  38. Aranda JV, Collinge JM, Zinman R, et al. Maturation of caffeine elimination in infancy. Arch Dis Child. 1979.PMID 533298DOI 10.1136/adc.54.12.946Tier 1
  39. European Food Safety Authority. Caffeine: EFSA explains risk assessment. Updated May 27, 2015.SourceTier 1
  40. European Food Safety Authority, NDA Panel. Scientific Opinion on the safety of caffeine. EFSA Journal 2015;13(5):4102. 2015-05.SourceTier 2
  41. U.S. Food and Drug Administration. Spilling the Beans: How Much Caffeine is Too Much?. Updated August 28, 2024.SourceTier 1
  42. U.S. Food and Drug Administration. Pure and Highly Concentrated Caffeine. Updated March 6, 2023.SourceTier 1
  43. Health Canada. Caffeine in foods. Updated April 2, 2025.SourceTier 1
  44. Food Standards Australia New Zealand. Caffeine powders and high caffeine content foods. Updated February 25, 2025.SourceTier 1
  45. Food Standards Australia New Zealand. Caffeine. Updated November 26, 2025.SourceTier 1
  46. legislation.gov.uk. Regulation (EU) No 1169/2011, Annex III (retained UK law).SourceTier 1
  47. NHS. Foods to avoid in pregnancy.SourceTier 2
  48. National Institute of Diabetes and Digestive and Kidney Diseases (LiverTox). LiverTox: Caffeine (NBK559835). Updated June 18, 2020.SourceTier 2
  49. National Institute of Child Health and Human Development (LactMed). Drugs and Lactation Database (LactMed): Caffeine (NBK501467). Updated April 15, 2026.SourceTier 2
  50. NIH Office of Dietary Supplements. Dietary Supplements for Exercise and Athletic Performance: Fact Sheet for Health Professionals. Updated April 1, 2024.SourceTier 2
  51. European Medicines Agency, Committee on Herbal Medicinal Products. Community herbal monograph on Paullinia cupana Kunth ex H.B.K. var. sorbilis (Mart.) Ducke, semen (EMA/HMPC/897344/2011, adopted 15 January 2013) and herbal summary page. Updated January 15, 2013.SourceTier 1
  52. ClinicalTrials.gov (U.S. National Library of Medicine). NCT02461693: Evaluating the Role of Expectations in Response to Caffeine Consumption: A Randomized Control Trial.SourceTier 1
  53. EUR-Lex (Publications Office of the European Union). Regulation (EU) No 1169/2011 on the provision of food information to consumers, consolidated text of 2018-01-01, Annex III. Updated January 1, 2018.SourceTier 1
  54. ClinicalTrials.gov (U.S. National Library of Medicine). NCT02109783: Caffeine, Genetic Variation and Athletic Performance.SourceTier 1
Reviewed by NootropicsWork Editorial Team, editorial team. Checklist logged . Next review due . Report an error